Clinical trial
A Study to Evaluate Lumasiran in Children and Adults With Primary Hyperoxaluria…
NCT03681184 · Alnylam Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT03681184 |
|---|---|
| Title | A Study to Evaluate Lumasiran in Children and Adults With Primary Hyperoxaluria Type 1 |
| Official title | ILLUMINATE-A: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study With an Extended Dosing Period to Evaluate the Efficacy and Safety of Lumasiran in Children and Adults With Primary Hyperoxaluria Type 1 |
| Acronym | ILLUMINATE-A |
| Lead sponsor | Alnylam Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Primary Hyperoxaluria Type 1 (PH1) |
| Intervention type | Drug |
| Interventions | Placebo, Lumasiran |
| Enrollment | 39 |
| Start date | Nov 27, 2018 |
| Primary completion | Nov 5, 2019 |
| Completion | Jan 12, 2024 |
| First posted | Sep 21, 2018 |
| Last update posted | Aug 12, 2024 |
| Countries | France, Germany, Israel, Netherlands, Switzerland, United Arab Emirates, United Kingdom, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: